Why Natural Desiccated Thyroid (NDT) is Not Recommended After Age 60
Natural desiccated thyroid is not recommended for patients over 60 with hypothyroidism because there is no evidence supporting its use over levothyroxine monotherapy, and it poses specific cardiovascular risks in elderly patients who are more vulnerable to the supraphysiologic T3 levels that NDT produces. 1
The Evidence Against NDT in Older Adults
Guideline Consensus
The 2012 AACE/ATA guidelines explicitly state that there is no evidence to support using desiccated thyroid hormone in preference to levothyroxine monotherapy, and therefore it should not be used for treating hypothyroidism 1. This represents unanimous expert opinion based on the lack of quality evidence and known risks.
Why This Matters More After Age 60
Cardiovascular vulnerability is the primary concern. The elderly population has:
- Higher rates of coronary artery disease, atrial fibrillation, and ischemic heart disease
- Greater sensitivity to thyroid hormone fluctuations
- Increased risk of precipitating cardiac events with supraphysiologic thyroid hormone levels 2
NDT contains both T4 and T3 in a fixed ratio (approximately 4:1), which creates transient supraphysiologic T3 peaks after ingestion. Unlike levothyroxine, which allows the body to convert T4 to T3 as needed, NDT delivers an immediate T3 load that elderly hearts may not tolerate well.
The Problem with Achieving Stable Control
The French Endocrine Society 2019 guidelines note that achieving normal thyroid function during levothyroxine treatment is already difficult in the elderly, with high rates of abnormal TSH levels 2. NDT makes this even more challenging because:
- The T3 component has a short half-life (24 hours vs 7 days for T4)
- Dosing adjustments are harder to titrate
- TSH monitoring becomes less reliable due to T3 suppression
Historical Usage Patterns Show Problems
A 1989 study found that inappropriate thyroid hormone use was more commonly associated with desiccated thyroid than with thyroxine in elderly patients 3. When inappropriate use occurred, it was more common in men and more often involved desiccated thyroid preparations, which were still commonly used in that age group at the time.
The Levothyroxine Standard
Levothyroxine monotherapy at 1.1-1.3 mcg/kg/day is the recommended treatment for hypothyroidism in elderly patients 2. The 2020 French guidelines specifically state there are no indications for associating levothyroxine with other thyroid preparations 2.
Practical Dosing Considerations
For patients over 50-60 years initiating therapy:
- Start with 50 mcg daily if no evidence of coronary heart disease 1
- Elderly patients often require less than half the replacement dose needed by younger patients 4
- The goal is to normalize TSH, not suppress it, to avoid cardiovascular and skeletal complications
Common Pitfalls to Avoid
Don't confuse patient preference with clinical benefit: While one RCT found 48.6% of patients preferred DTE over levothyroxine 5, this preference was associated with modest weight loss (3-4 lbs) rather than improved quality of life or symptom scores. The same study found no differences in neurocognitive measurements between treatments.
Recognize that "feeling better" may reflect weight loss, not better thyroid control: The weight loss effect of DTE is likely due to mild hyperthyroidism from the T3 component—exactly what we want to avoid in elderly patients with cardiovascular risk.
Don't be swayed by historical use: Just because NDT was used in the past doesn't make it appropriate. A 2024 systematic review concluded that most studies of DTE are hampered by inferior design, and data on long-term effects and side effects are lacking 6.
The Bottom Line for Clinical Practice
Use levothyroxine monotherapy exclusively in patients over 60 with hypothyroidism. The cardiovascular risks of NDT's unpredictable T3 peaks, combined with the difficulty achieving stable thyroid control in elderly patients and the complete absence of evidence supporting NDT's superiority, make this a clear-cut decision. The goal in elderly patients is to avoid both over- and under-replacement, as population studies have shown associations with adverse cardiovascular and skeletal events 7.
If a patient is already on NDT and doing well, the decision to switch requires individualized assessment, but new prescriptions of NDT in patients over 60 should not be initiated 1.